|
|
|
|
|
|
| Open:
|
1.10 |
|
Volume:
|
195 |
| High:
|
1.15 |
|
52Wk High:
|
4.20 |
| Low:
|
1.00 |
|
52Wk Low:
|
1.00 |
|
|
|
|
|
|
|
|
|
|
|
2600 Stemmons Frwy
Dallas, TX 75207, US
|
|
Pharmaceutical Preparations |
| |
|
|
|
 |
 |
|
 |
|
Free Registration enables all site features including Email Alerts, RSS Feeds, Charts & Reports, SEC Filings, and Executive & Company Profiles.
|
 |
 |
 |
 |
|
|
 |
|
 |
|
|
|
|
Board Member Report includes all current and historical board members, their board committees, whether they are the chair of each committee, the date they became a member of the board and their Job Title if they are also an executive of the firm. Also, you can create an email alert for any board member right from the Board Member report!
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SEC filings are made available through
SECFilings.com – our free SEC filings portal with e-mail alert
and RSS capabilities. Clicking on the links to the left will bring you to the
corresponding page on SECFilings.com where you can login with your
ExecutiveDisclosure.com username and password to instantly view filings and
setup e-mail or RSS alerts.
|
|
 |
 |
 |
|
|
|
|
Company Average Compensation vs. Average Compensation for all Same Market Cap Companies in Same Industry chart compares the average pay for the company against all companies in the same industry and market cap using actual dollar figures.
|
|
|
|
|
|
 |
|
 |
|
|
 |
|
|
|
|
Company Average Compensation vs. Industry Average Compensation chart compares the average pay for the company against all companies in the same industry using actual dollar figures, making it easy to see how the current company's compensation practices compare against the industry average.
|
|
|
|
|
|
|
|
|
|
|
|
Company Average Compensation % Trend vs. Company Stock Prices % Trend chart compares the year over year percentage change in the average compensation package against the year over year percentage change in the company's stock price.
|
|
|
|
|
|
 |
|
|
 |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| Rosemary Mazanet, M.D. became a director of the Company in May 2006. Dr. Mazanet currently serves as Managing Director of Argenis Capital. She served as Chief Executive Officer of Breakthrough Therapeutics, LLC, a privately held development stage... (Read
more) |
|
05/19/2006
8076.00 |
|
|
|
|
| |
|
|
|
|
| DAVID P. LUCI, ESQ., was appointed as a Director of MacroChem on April 18, 2008. On April 22, 2008 Mr. Luci was appointed President & Chief Business Officer of MacroChem. From March 2008 to April 2008, Mr. Luci served as Chief Financial Officer and... (Read
more) |
|
12/03/2007
04/18/2008
16667.00 |
|
|
|
|
| |
|
|
|
|
| JEFFREY B. DAVIS has served as a Director of MacroChem since 2005. Since January 2008, Mr. Davis has served as Chief Executive Officer of Access Pharmaceuticals, Inc. (OTC BB: ACCP) and also since 1997, Mr. Davis has been President of SCO Securities... (Read
more) |
|
2005
|
|
|
|
|
| |
|
|
|
|
| Mark J. Ahn, Ph.D. (45) has been one of our directors since 2007. Dr. Ahn is Professor and Chair, Science & Technology Management with a joint appointment from the faculties of Commerce & Administration and Science, Victoria University of... (Read
more) |
|
2007
244375.00 |
|
|
|
|
| |
|
|
|
|
| MARK J. ALVINO has served as a Director of MacroChem since May 2007. Since June 2007, Mr. Alvino has served as a Managing Director of Griffin Securities. Prior to joining Griffin Securities, Mr. Alvino served as Managing Director at SCO Financial... (Read
more) |
|
05/2007
|
|
|
|
|
| |
|
|
|
|
| Mr. Phillip S. Wise has been Access" Vice President Business Development since June 2006. Mr. Wise was Vice President of Commercial and Business Development for Enhance Pharmaceuticals, Inc. and Ardent Pharmaceuticals, Inc. from 2000 until 2006.... (Read
more) |
|
06/01/2006
200000.00 |
|
|
|
|
| |
|
|
|
|
| Dr. Esteban Cvitkovic became a director in February 2007 as Vice Chairman (Europe) and is also a consultant to the Company as Senior Director, Oncology Clinical Research & Development. Recently, the oncology-focused CRO, Cvitkovic & Associes... (Read
more) |
|
02/08/2007
|
|
|
|
|
| |
|
|
|
|
| Mr. Steven H. Rouhandeh became a director and Chairman of the Board on March 4, 2008. He is a Chief Investment Officer of SCO Capital Partners, L.P., a New York based life sciences fund. Mr. Rouhandeh also is a founder of SCO Financial Group LLC, a... (Read
more) |
|
03/04/2008
|
|
|
|
|
| |
|
|
|
|
| Mr. Stephen R. Seiler has been our President and Chief Executive Officer and a Director since January 2007. Until recently, Mr. Seiler had been Acting Chief Executive Officer of Effective Pharmaceuticals, Inc. and advising other companies in the... (Read
more) |
|
01/2007
01/2007
350000.00 |
|
|
|
|
| |
|
|
|
|
| David P. Nowotnik, Ph.D. has been Senior Vice President Research and Development since January 2003 and was Vice President Research and Development from 1998. From 1994 until 1998, Dr. Nowotnik had been with Guilford Pharmaceuticals, Inc. in the... (Read
more) |
|
1998
253620.00 |
|
|
| | |